source
- AbbVie’s dual-acting myeloma drug etentamig meets main Phase 3 goal, showing longer progression-free survivalAbbVie announced that its bispecific antibody etentamig achieved the primary endpoint in a Phase 3 trial for patients with multiple myeloma who have progressed after two or more prior therapies. Th…
- Licensing deals with Chinese biotech stay strong as big pharma pours $550M+ into cancer and obesity pipelinesWestern drug developers continue to sign licensing agreements with Chinese biotechnology firms at a steady pace, according to recent data visualizations. More than 100 such deals have been announc…